cases of and ∼600,000 deaths due to C. neoformans meningitis globally, with most cases occurring in subSaharan Africa [5] . Although the incidence of C. neoformans meningitis has decreased dramatically in the United States and parts of the world where antiretroviral therapy is available [1] , this disease has emerged as an important complication of solid organ transplantation [6, 7] and immune reconstitution syndrome [8] . HIV-associated cryptococcosis almost always occurs when an individual's CD4 + T cell level is significantly !200 cells/mL [9] , but there are no known factors that differentiate HIV-infected individuals who will develop cryptococcosis from those who will not. The ability to identify patients who are at the highest risk for the development of cryptococcosis would be a major advance, because available therapies are often unable to cure cryptococcosis in persons who are immunosuppressed.
In addition to HIV infection, common-variable im-munodeficiency (CVID) and X-linked hyper IgM (XHIM) have been associated with a higher risk for the development of cryptococcosis [10] [11] [12] . Reduced expression of CD27 + CD19 + IgM + IgD Ϫ B cells (hereafter, "IgM + memory B cells") can occur in each of these conditions [13] [14] [15] . IgM + memory B cells, which compose ∼50% of the circulating memory B cell repertoire, have been implicated in immunity to Streptococcus pneumoniae [16] [17] [18] , and reduced levels have been linked to impaired responses to pneumococcal vaccine [14, 17] . Because levels of IgM + memory B cells are reduced during HIV infection [13, [18] [19] [20] , and because HIV-infected individuals are at increased risk for the development of cryptococcosis [21] , we determined the level of IgM + memory B cells in subjects with and subjects without HIV-associated cryptococcosis.
SUBJECTS, MATERIALS, AND METHODS
Study population. Cohort 1 consisted of 20 HIV-uninfected subjects recruited from the Adult Ambulatory Care Clinic at Jacobi Hospital (Bronx, NY) (the HIVϪ group) and 59 HIVinfected subjects who attended outpatient clinics at the Jacobi AIDS Center and the Montefiore Center for Positive Living (Bronx) between September 2006 and December 2007. Of the HIV-infected subjects, 29 had a history of cryptococcosis (the HIV+CN+ group) and 30 had no history of cryptococcosis (the HIV+CNϪ group). A history of cryptococcosis was defined as the recovery of C. neoformans from cerebrospinal fluid (CSF) or blood and/or a blood or CSF cryptococcal antigen titer of 11:8. Cryptococcal antigen titers at the time of study recruitment were determined using the CALAS system (Meridian Biosciences).
Cohort 2 consisted of the following 31 subjects enrolled in the Multicenter AIDS Cohort Study: 8 HIV-infected subjects who subsequently developed cryptococcosis (the HIV+CN+ group), 8 HIV-infected subjects without cryptococcosis who were matched to the HIV+CN+ group on the basis of CD4 + T cell level (the HIV+CNϪ group), and 15 HIVϪ subjects with no historyof cryptococcosis who were matched to the HIV+CN+ group on the basis of age and geographic region (the HIVϪ group) [22] .
For cohort 1, peripheral blood mononuclear cells (PBMCs) and serum samples were studied. Serum specimens underwent heat treatment for 30 min at 56ЊC and were stored at Ϫ80ЊC before use. For cohort 2, banked frozen PBMCs in a final concentration of 10% dimethyl sulfoxide per vial (prepared using the Controlled Rate Freezing System [Gordinier Electronics]) were used.
This research protocol was reviewed and approved by the institutional review boards of Albert Einstein College of Medicine, Jacobi Hospital, and Montefiore Hospital. All human participants in this study gave written informed consent.
Characterization of circulating memory B cell repertoire.
Memory B cell expression was analyzed by flow cytometry. For cohort 1, PBMCs were separated from blood by density-gradient centrifugation on Ficoll-Paque (GE Healthcare Bio-Sciences AB), using published protocols [23, 24] . The cells were stained with fluorescein isothiocyanate anti-human CD27 (Ebiosciences), phycoerythrin-Cy7 anti-human CD19 (E-biosciences), phycoerythrin anti-human IgD (Southern Biotech), and cyanine-5 anti-human IgM, Fc5m fragment-specific (Jackson Immunoresearch) for 1 h at 4ЊC. Cells were then washed and fixed with 2% paraformaldehyde. For cohort 2, frozen cells were thawed in a 37ЊC water bath for 1 min, and warm RPMI-1640 (Cellgro) supplemented with 10% sterile heat-inactivated fetal bovine serum (Atlanta Biologicals) and 1% penicillinstreptomycin solution (Cellgro) was added. Cells were then centrifuged, washed, counted, and stained as described above. ). The samples were studied in a blinded, coded fashion. Measurement of total immunoglobulin concentrations. Total serum IgM and IgG levels were determined by enzyme-linked immunosorbent assay (ELISA), as described elsewhere [25] , and the IgG2 level was measured by radial immunodiffusion kits (The Binding Site) according to the manufacturer's protocol.
Measurement of antibodies to GXM. Serum titers of GXM-reactive IgM and IgG for individuals in cohort 1 were determined by a GXM antigen capture ELISA, as described elsewhere [26] . Titers for subjects in cohort 2 were reported previously [22] .
Statistical analysis. After completion of the experiments, results were unblinded, and statistical analyses were performed using Stata, version 9.2 (StataCorp). Statistical significance was defined as a 2-tailed P value of !.05. Spearman rank correlation coefficients were used to look for correlations between variables. In cohort 1, univariate analyses were performed on ordinal and continuous variables, using the Mann-Whitney U test. The nadir CD4 + T cell count (р200 vs. 1200 cells/mL) and the per- were analyzed as continuous variables and transformed into categorical variables. Univariate logistic regression was performed, followed by a stepwise reverse nonconditional procedure, to assess whether the IgM level or the percentage of memory B cells expressing IgM was a significant and independent predictor of cryptococcosis. In cohort 2, Wilcoxon signed rank tests were used to assess differences between HIV+CN+, HIV+CNϪ, and HIVϪ control subjects. Hypothesis testing was performed using the Mantel-Haenszel test. For cells with zero counts, the Fleiss adjusted odds ratio, which adds 0.5 to each cell, was used for estimation.
RESULTS
Subject characteristics. Table 1 shows the clinical characteristics, CD4
+ T cell counts, and plasma HIV RNA levels for subjects in cohort 1 and those in cohort 2. In cohort 1, HIV+CNϪ subjects had significantly higher CD4 + T cell counts and lower plasma HIV RNA levels, compared with HIV+CN+ subjects. In cohort 2, samples from HIV+CN+ subjects were obtained a mean of 1146 days before cryptococcosis was diagnosed. At the time of the diagnosis of cryptococcosis, 1 subject in the HIV+CN+ group and none of the subjects in the HIV+CNϪ group had a CD4 + T cell count of !200 cells/mL.
( Comparison of HIV+CN+ subjects and HIV+CNϪ subjects in cohort 2 showed that neither the number of un-classswitched memory cells nor the number of class-switched memory cells was significantly associated with C. neoformans disease status. For both cohorts, there was no significant difference in the percentages of memory cells that were class switched or expressed IgD only between subjects with and subjects without cryptococcosis.
Total immunoglobulin levels and antibodies to GXM. There were no significant differences in total IgM, IgG, or IgG2 levels between the HIV+CN+ and HIV+CNϪ groups in cohort 1. The immunoglobulin profiles of subjects in cohort 2 were reported previously [22] . The median titer of GXM-binding IgM in the HIV+CN+ group was significantly lower than that in the HIV+CNϪ group (220 vs. 575 [ ]; data not shown). P p .005 The level of GXM-reactive IgG did not differ significantly between the groups.
DISCUSSION
This study investigated the hypothesis that a reduction in levels of IgM + memory B cells might be a risk factor for the development of HIV-associated cryptococcosis. Our results showed that HIV+CN+ subjects had significantly lower levels of IgM + memory B cells than did HIV+CNϪ subjects. Strikingly, the level of expression was comparable between and an independent predictor of C. neoformans disease status in HIV+CN+ subjects, whether samples were obtained years before (for cohort 2) or years after (for cohort 1) development of cryptococcosis.
The level of IgM + memory B cells is reduced in persons with HIV infection [13, [18] [19] [20] . In our study, the percentage of memory B cells that expressed IgM was statistically similar for HIV+CNϪ subjects and HIVϪ subjects. However, HIV+CNϪ subjects in cohort 2 had 25% fewer IgM + memory B cells than did HIVϪ subjects, and HIV+CNϪ subjects in cohort 1 had a higher level of IgM + memory B cells and a lower total B cell level than did HIVϪ subjects. Additionally, the HIVϪ subjects in cohort 2 had lower levels of IgM + memory B cells than did the HIVϪ subjects in cohort 1. This reduction might be a function of age, because IgM + memory B cell levels reportedly decrease with increasing age [17] . In a study from another group, the level of IgM + memory B cells among HIV-infected individuals with a CD4 + T cell count of 1300 cells/mL was higher than levels among HIV-infected individuals with a CD4 + T cell count of !300 cells/mL and HIV-uninfected control subjects [18] . Given that HIV+CNϪ subjects in cohort 1 had a CD4 + T cell count of 1500 cells/mL, their level of IgM + memory B cells might reflect B cell activation [18, 27] . Alternatively, greater levels of IgM + memory B cells could reflect antiretroviral therapy-associated immune reconstitution [20, 28, 29] . There was no correlation between the percentage of memory B cells expressing IgM and viral load in either cohort or between the percentage of memory B cells expressing IgM, CD4 + T cell levels, and/or C. neoformans disease status in cohort 1. We were not able to assess these associations in cohort 2 because the subjects were matched on the basis of CD4 + T cell count. Nonetheless, multivariate analysis showed that the percentage of memory B cells expressing IgM and CD4 + T cell counts were each independent predictors of C. neoformans disease status in cohort 1. The link between CD4 + T cell level and cryptococcosis was expected. However, the relationship between IgM + memory B cell expression and cryptococcosis, which was demonstrated in both cohorts, including in matched subjects in cohort 2, is striking and novel. Although cohort 2 was small, precluding multivariate analysis, the odds ratio for the relationship between the percentage of memory B cells expressing IgM and disease status was even higher than in cohort 1.
Remarkably, the level of IgM + memory B cell expression in HIV+CN+ subjects in cohort 2 was predictive of future development of cryptococcosis. This suggests that the level of IgM + memory B cells could, before T cell deficiency progresses, portend a risk for the development of cryptococcosis. This concept is reinforced by our data showing that a similar percentage of memory B cells expressing IgM was observed in a predisease cohort (cohort 2), in a postdisease cohort (cohort 1), and in 2 HIV-uninfected subjects with cryptococcosis. Thus, it is possible that the risk for the development of cryptococcosis could be defined by a level of IgM + memory B cell expression that decreases below a certain threshold. Future studies involving a larger cohort will address this question. The longitudinal effect of HIV infection on IgM + memory B cells is unknown and requires further study. Nonetheless, the level of IgM + memory B cells in HIV+CN+ subjects was lower than that in HIV+CNϪ subjects in cohort 2, despite the fact that the former subjects had a CD4 + T cell count of 1300 cells/mL and were 13 years away from their disease event. Hence, our data suggest that part of the risk for the development of cryptococcosis could be independent of HIV infection. As such, we wonder whether certain cases of cryptococcosis might reflect an underlying deficiency in IgM + memory B cells that is enhanced by HIV infection. This could apply to HIV-associated and HIV-unassociated cryptococcosis. In persons with HIV infection, the risk for the development of cryptococcosis might stem from T cell deficiency and an HIV-associated reduction in IgM + memory B cells, whereas in persons without HIV infection, cryptococcosis might stem from another etiological cause of the reduction in IgM + memory B cells, such CVID or XHIM, disorders that are also associated with T cell defects [30, 31] . The latter could also explain sporadic disease, which remains completely unexplained. IgM + memory B cells produce naturally occurring IgM, which has been shown to enhance resistance to experimental infection with influenza virus [32] , S. pneumoniae [17, 33] , and West Nile virus [34] . In humans, pneumococcal vaccination increases memory B cell expression [35] , and reduced expression of memory B cells has been associated with a reduced vaccine response [14, 17] . To our knowledge, levels of IgM produced by IgM + memory B cells have not been evaluated previously in patients with C. neoformans disease. However, serological studies found less GXM-reactive IgM in HIV-infected subjects, compared with HIV-uninfected subjects [22, 25, 26, 36] , and in solid-organ transplant recipients who developed cryptococcosis, compared with those who did not [6] . In this study, HIV+CN+ subjects in cohort 1 had lower levels of GXM-reactive IgM than did HIV+CNϪ subjects; however, because these HIV+CN+ subjects also had persistent antigenemia, this finding could be confounded by immune complexes containing IgM and GXM [37, 38] . Nonetheless, it is possible that GXM-reactive IgM could be a surrogate for levels of IgM + memory B cells in individuals who have not had cryptococcosis, but this question requires further study. The way in which IgM produced by memory B cells and/or GXM-reactive IgM could influence cryptococcal pathogenesis also requires further study, but several mechanisms are possible. Because GXM-binding antibodies enhance host defense against cryptococcosis [39, 40] , GXM-reactive IgM could enhance resistance by acting as an opsonin. Whether human GXM-reactive IgM is derived from IgM + memory B cells is currently under investigation in our laboratory. Another mechanism by which IgM + memory B cells could enhance host defense is through the production of chemokines and cytokines. TNF-a, IFN-g, and IL-12, which are important for resistance to C. neoformans, are each produced by IgM + memory B cells [41] . In addition, IL-6, a cytokine that is also produced by B cells [42] , was necessary for a protective immune response to experimental C. neoformans infection in humans and mice [43, 44] .
No significant associations were found between the expression of class-switched and/or IgD-only memory cells and C. neoformans disease status. The percentage of memory cells that were un-class switched was greater among HIV+CN+ subjects than among subjects with no history of cryptococcosis, but this is most likely a reciprocal increase due to the decrease in levels of IgM + memory B cells. There were no significant differences in the number of un-class-switched memory cells between subjects with and subjects without a history of cryptococcosis in either cohort. HIV+CN+ subjects in cohort 1 had significantly fewer class-switched memory cells than did HIV+CNϪ subjects and HIVϪ subjects. This might be a function of the lower CD4 + T cell levels in subjects from cohort 1 who had a history of cryptococcosis, because class-switched memory expression has been correlated with CD4 + T cell levels [18] . In summary, our data suggest that levels of IgM + memory B cells might predict susceptibility to cryptococcosis, with the caveat that our study has certain limitations. It was retrospective, and the samples from cohort 2 were matched for CD4 + T cell level, which hampered our ability to determine the relationship between T cell deficiency and IgM + memory B cell expression. On the other hand, because the subjects in cohort 1 were not matched, we could not assess the effect of the levels of IgM + memory B cells on C. neoformans disease status as an independent variable. Studies to determine the effect of IgM + memory B cells on the risk for the development of cryptococcosis and the effect of HIV disease progression on levels of IgM + memory B cells are each needed. The number of B cells recovered from subjects in cohort 2 was ∼16% less than the number recovered from subjects in cohort 1, most likely because of thawing and processing of stored samples. Although we do not think these limitations affect the conclusions of our study, a larger study is needed to validate our hypothesis. If our hypothesis is correct, the level of IgM + memory B cells could emerge as a parameter to identify HIV-infected patients and, possibly, other patients who are at risk for the development of cryptococcosis. Such a marker would be helpful in guiding the use of antifungal prophylaxis and/or immune modulation to prevent cryptococcosis in patients with HIV infection, and potentially, in patients with immunodeficiency or who undergo organ transplantation.
